The number of pharmaceutical-biotech alliances has doubled in the last five years, according to a new report from business intelligence firm Cutting Edge Information.

The report features 11 case studies and more than 90 metrics, which Cutting Edge says confirm that well-run pharmaceutical-biotech alliances factor heavily in becoming, and remaining, “pharmaceutical powerhouses.”

Titled “Building Pharmaceutical-Biotechnology Partnerships,” the 145-page study is available online at It shows how companies such as Pfizer, Aventis, GlaxoSmithKline, AstraZeneca, Amgen, and Chiron execute their alliances.

One profiled company that the study notes as an example manages more than 250 R&D partnerships. It says the firm attributes much of its financial and market success to its alliance management experience.

“Drugs produced by pharma-biotech alliances are 30 percent more likely to succeed in winning FDA approval than those developed by a sole company, which is why they are so attractive in today’s market,” says Cutting Edge CEO Jason Richardson. “The companies profiled in this report have proven experience in structuring alliances to produce blockbuster products.”

In addition, the following metrics and practices are highlighted in the report:

  • Number of alliance-dedicated FTEs in place at pharmaceutical and biotech companies

  • Dollar values and strategic goals for products ranging from $400 million to $2 billion

  • Alliance budget allocations by function

  • Alliance-function organizational charts

  • Alliance-threatening (or saving) differences in what pharmaceutical and biotech partners value
  • Cutting Edge: